Sign In
Buy SLDB
$8.30
-0.0300 (-0.360%)
At Close: Jun 22, 2026
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2022
02:02pm, Monday, 17'th Oct 2022 Benzinga
Upgrades
For Citi Trends Inc (NASDAQ:CTRN), Gordon Haskett upgraded the previous rating of Reduce to Hold. For the second quarter, Citi Trends had an EPS of $0.31, compared to year-ago quarter EPS of
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
04:06pm, Friday, 30'th Sep 2022 Benzinga
Gainers
Ainos, Inc. (NASDAQ: AIMD) shares surged 55.1% to $2.1411 after the company reported results from the additional preclinical study of its low-dose oral interferon formulation against Omicron.
Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement
11:00am, Friday, 30'th Sep 2022 GlobeNewswire Inc.
- Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases, led by industry veteran and current AavantiBio CEO, Bo Cumbo -
Solid Biosciences Inc. (SLDB) Reports Q2 Loss, Tops Revenue Estimates
01:15pm, Thursday, 11'th Aug 2022 Zacks Investment Research
Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -4.76% and 77.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Solid Biosciences Provides Second Quarter 2022 Business Update and Financial Results
11:53am, Thursday, 11'th Aug 2022 GlobeNewswire Inc.
- Transition to transient transfection-based manufacturing process continues for SGT-001; Company expects to continue dosing patients in 2023 -
Femasys Inc. (FEMY) Reports Q2 Loss, Tops Revenue Estimates
09:45pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
Femasys Inc. (FEMY) delivered earnings and revenue surprises of 15.38% and 1%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
MannKind (MNKD) Reports Q2 Loss, Tops Revenue Estimates
09:15pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
MannKind (MNKD) delivered earnings and revenue surprises of -22.22% and 15.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
What 4 Analyst Ratings Have To Say About Solid Biosciences
03:33pm, Thursday, 19'th May 2022 Benzinga
Over the past 3 months, 4 analysts have published their opinion on Solid Biosciences (NASDAQ:SLDB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding
Solid Biosciences Inc. (SLDB) CEO Ilan Ganot on Q1 2022 Results - Earnings Call Transcript
05:25pm, Saturday, 30'th Apr 2022
Solid Biosciences Inc. (NASDAQ:SLDB ) Q1 2022 Results Conference Call April 27, 2022 8:00 AM ET Company Participants Caitlin Lowie - VP, Communications and IR Ilan Ganot - Co-Founder, President and CE
10 Biggest Price Target Changes For Thursday
11:35am, Thursday, 28'th Apr 2022 Benzinga
Needham lowered MKS Instruments, Inc. (NASDAQ: MKSI) price target from $185 to $175. MKS Instruments shares rose 3.6% to $116.01 in pre-market trading.
Piper Sandler cut the price target for PayPal
Solid Biosciences Inc. (SLDB) Reports Q1 Loss, Misses Revenue Estimates
02:35pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -22.22% and 46.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock
Solid Biosciences Inc. (SLDB) Reports Q1 Loss, Misses Revenue Estimates
12:18pm, Wednesday, 27'th Apr 2022
Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -22.22% and 46.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock
Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy
11:30am, Wednesday, 27'th Apr 2022 GlobeNewswire Inc.
- IGNITE DMD functional and durability patient data support advancement of SGT-001; Program transitioning to a commercially scaled transient transfection-based manufacturing process -
Sanofi (SNY) Stock Outperforms Industry YTD: What Lies Ahead?
12:23pm, Thursday, 07'th Apr 2022 Zacks Investment Research
Here we discuss some factors that have been driving Sanofi's (SNY) stock and its outlook for the future.
Alnylam's (ALNY) Vutrisiran NDA Faces Delay in FDA Decision
01:25pm, Tuesday, 05'th Apr 2022 Zacks Investment Research
The FDA needs time to review new information incorporated into Alnylam's (ALNY) vutrisiran NDA related to a new secondary packaging and labeling facility, which has been cited as a reason for the dela
